Your browser is no longer supported. Please, upgrade your browser.
Spruce Biosciences, Inc.
Index- P/E- EPS (ttm)- Insider Own19.40% Shs Outstand23.28M Perf Week-4.52%
Market Cap268.89M Forward P/E- EPS next Y-2.37 Insider Trans-9.84% Shs Float22.76M Perf Month-21.21%
Income- PEG- EPS next Q-0.46 Inst Own97.30% Short Float2.00% Perf Quarter-54.91%
Sales- P/S- EPS this Y-125.70% Inst Trans-0.06% Short Ratio6.28 Perf Half Y-45.88%
Book/sh6.04 P/B1.93 EPS next Y-8.70% ROA- Target Price- Perf Year-
Cash/sh6.43 P/C1.81 EPS next 5Y- ROE- 52W Range12.00 - 35.60 Perf YTD-52.16%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-67.33% Beta-
Dividend %- Quick Ratio22.10 Sales past 5Y- Gross Margin- 52W Low-3.08% ATR0.90
Employees19 Current Ratio22.10 Sales Q/Q- Oper. Margin- RSI (14)30.14 Volatility6.05% 6.51%
OptionableNo Debt/Eq0.03 EPS Q/Q27.80% Profit Margin- Rel Volume0.70 Prev Close12.14
ShortableYes LT Debt/Eq0.03 Earnings- Payout- Avg Volume72.26K Price11.63
Recom1.70 SMA20-16.03% SMA50-23.07% SMA200-40.25% Volume50,295 Change-4.20%
Apr-26-21Resumed Credit Suisse Outperform $26
Nov-03-20Initiated SVB Leerink Outperform $35
Nov-03-20Initiated RBC Capital Mkts Outperform $28
Nov-03-20Initiated Credit Suisse Outperform $28
Nov-03-20Initiated Cowen Outperform $44
May-24-21 08:01AM  
May-13-21 04:05PM  
May-12-21 04:05PM  
Mar-22-21 04:05PM  
Mar-17-21 08:00AM  
Mar-02-21 08:00AM  
Feb-17-21 04:05PM  
Jan-12-21 05:10AM  
Jan-06-21 08:00AM  
Dec-17-20 04:05PM  
Nov-18-20 04:05PM  
Nov-04-20 04:05PM  
Oct-16-20 07:38PM  
Oct-14-20 04:05PM  
Oct-09-20 03:49PM  
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). It offers tildacerfont, which is in Phase II clinical trial for children with classic CAH; and for females with polycystic ovary syndrome. In addition, it is involved in developing CAHmelia-203 which is in Phase 2b clinical trial for adult patients with classic CAH with poor disease control; and CAHmelia-204, which is in second Phase 2b clinical trial in adult patients with classic CAH with good disease control. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SIMPSON CAMILLA VDirectorMay 20Option Exercise0.85334284334May 21 09:10 PM
SIMPSON CAMILLA VDirectorMay 20Sale15.293345,1070May 21 09:10 PM
Novo Holdings A/S10% OwnerMay 19Sale13.90475,0006,602,5004,514,336May 21 04:32 PM
SIMPSON CAMILLA VDirectorApr 30Option Exercise0.8514,04511,93814,045May 04 09:09 PM
SIMPSON CAMILLA VDirectorApr 30Sale16.1414,045226,6640May 04 09:09 PM
Novo Holdings A/S10% OwnerOct 14Buy15.00250,0003,750,0004,989,336Oct 16 04:49 PM
RiverVest Venture Fund III, L.10% OwnerOct 14Buy15.00250,0003,750,0002,148,281Oct 16 12:34 PM
Muralidhar BaliDirectorOct 14Buy15.00200,0003,000,0001,792,518Oct 16 12:24 PM
O'Donnell NiallDirectorOct 14Buy15.00250,0003,750,000695,905Oct 16 12:21 PM
Chaya Moghrabi DinaDirectorOct 14Buy15.00250,0003,750,0002,161,022Oct 16 12:14 PM
Omega Fund VI, L.P.Former 10% OwnerOct 14Buy15.00250,0003,750,0002,161,022Oct 16 12:15 PM
HANSSON JONASDirectorOct 14Buy15.00250,0003,750,0002,033,621Oct 16 12:07 PM
HealthCap VIII, L.P.Former 10% OwnerOct 14Buy15.00250,0003,750,0002,033,621Oct 16 12:08 PM